Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist Pl8177 in Ulcerative Colitis
Palatin宣佈完成對口服給藥的黑色素皮質激素激動劑Pl8177在潰瘍性結腸炎中進行的二期研究患者招募。
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist Pl8177 in Ulcerative Colitis
Palatin宣佈完成對口服給藥的黑色素皮質激素激動劑Pl8177在潰瘍性結腸炎中進行的二期研究患者招募。
使用瀏覽器的分享功能,分享給你的好友吧